Specify Company / Ticker to Get the Summary
Dividend History PHVS
Dividend Analytics PHVS
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Pharvaris BV
PHVSPharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Address: Grafenauweg 8, Zug, Switzerland, 6300
Analytics
WallStreet Target Price
34.24 USDP/E Ratio
–Dividend Yield
–Financials PHVS
Results | 2019 | Dynamics |